

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT7188281

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
CSPC DOPHEN CORPORATION	02/17/2022
RECEIVING PARTY DATA	
Name:	CSPC MEGALITH BIOPHARMACEUTICAL CO., LTD.
Street Address:	226 HUANGHE AVENUE
City:	SHIJIAZHUANG, HEBEI
State/Country:	CHINA
PROPERTY NUMBERS Total: 5	
Property Type	Number
Patent Number:	10357472
Patent Number:	10639291
Patent Number:	10471037
Application Number:	16526979
PCT Number:	US2020057761
CORRESPONDENCE DATA	
Fax Number:	(650)494-0792
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	6508135736
Email:	jmerkelbach@mofo.com
Correspondent Name:	JIAN XIAO
Address Line 1:	MORRISON & FOERSTER LLP
Address Line 2:	755 PAGE MILL ROAD
Address Line 4:	PALO ALTO, CALIFORNIA 94304-1018
ATTORNEY DOCKET NUMBER:	72069-28000.00
NAME OF SUBMITTER:	JIAN XIAO
SIGNATURE:	/Jian Xiao/
DATE SIGNED:	02/22/2022
Total Attachments: 6	
source=72069-2800000-Entity-Assgn#page1.tif	
source=72069-2800000-Entity-Assgn#page2.tif	

source=72069-2800000-Entity-Assgn#page3.tif

source=72069-2800000-Entity-Assgn#page4.tif

source=72069-2800000-Entity-Assgn#page5.tif

source=72069-2800000-Entity-Assgn#page6.tif

ENTITY TO ENTITY ASSIGNMENT

This Assignment is by:

Assignor: CSPC Dopphen Corporation
Address: 4070 Truxel Road
Sacramento, California 95834
A juristic entity duly organized under and pursuant to the laws of: Delaware

(referred to in this Assignment as "Assignor"), which is the sole and exclusive owner, by assignment, of the patents and applications identified in Exhibit A.

This Assignment is to:

Assignee: CSPC Megalith Biopharmaceutical Co., Ltd.
Address: 226 Huanghe Avenue
Shijiazhuang, Hebei, China
A juristic entity duly organized under and pursuant to the laws of: China

(referred to in this Assignment as "Assignee"), which desires to acquire the entire right, title and interest in, to and under said patent application and the inventions covered thereby.

For good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and to the extent that the Assignor has not done so already via a prior agreement with the Assignee or a predecessor in interest of the Assignee, or if the Assignor has already done so via a prior agreement with the Assignee or a predecessor in interest of the Assignee then in confirmation of any obligation to do so in said prior agreement

1. Assignor hereby sells, assigns, transfers and sets over, to Assignee, its successors, legal representatives and assigns, Assignor's entire right, title and interest in and to the above-mentioned inventions, application for letters patent, and any and all non-provisionals, divisions, continuations, and continuations-in part claiming priority thereto or the benefit thereof, substitutions of said applications, and any and all letters patent or patents in the United States of America and all foreign countries or jurisdictions which may be granted therefor and thereon, including, without limitation, any modifications to such letters patent or patents such as through reissue, re-examination or other post-grant proceeding, and any and all extensions of said letters patent or patents, and all rights under the International Convention for the Protection of Industrial Property, the same to be held and enjoyed by Assignee (including any right to institute actions and to recover damages for past, present and future infringement, and any and all rights to claim priority to said application and any and all applications claiming priority thereto or based on said inventions), for its own use and the use of its successors, legal representatives and assigns, to the full end of the term or terms for which letters patent or patents may be granted, as fully and entirely as the same would have been held and enjoyed by Assignor, had this sale and assignment not been made.

2. Assignor hereby authorizes and requests the Commissioner for Patents in the United States to issue the above mentioned letters patents of the United States and any reissue, reexamination, review, or extension thereof to and in the name of Assignee as the assignee of said inventions and the letters patent to be issued thereon for the sole use of Assignee, its successors, legal representatives and assigns.


3. Assignor hereby grants Assignee's attorneys, all of Morrison & Foerster LLP (or as needed attorneys of the applicable country appointed and authorized by Morrison & Foerster LLP), the power to insert on this assignment any further identification which may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark office or any foreign patent issuing authority for recordation of this document, including the power to insert on this assignment the application number and filing date of said application when known.

4. This assignment may be executed in one or more counterparts, with the same effect as if each signature were on the same document. Each counterpart so executed shall be deemed to be an original, and all such counterparts shall be construed together and shall constitute one agreement.

In witness whereby, executed by the undersigned on the date(s) opposite the undersigned name(s).

ASSIGNOR:

Date: 2022.2.17

Signature: 

Name: Qingxi Wang

Title: President

Company: CSPC Dophen Corporation

ASSIGNEE:

Date: _____

Signature: _____

Name:

Title:

Company: CSPC Megalith Biopharmaceutical Co., Ltd.

sf-4685642

Exhibit A

Country	Application No.	Filing Date	Patent No.	Issue Date	Title
US	15/317,907	06/11/2015 (Int'l Date)	10,357,472	07/23/2019	HOMOGENOUS ANTIBODY DRUG CONJUGATES VIA ENZYMATIC METHODS
US	15/986,665	05/22/2018	10,639,291	05/05/2020	HOMOGENOUS ANTIBODY DRUG CONJUGATES VIA ENZYMATIC METHODS
US	15/986,668	05/22/2018	10,471,037	11/12/2019	HOMOGENOUS ANTIBODY DRUG CONJUGATES VIA ENZYMATIC METHODS
US	16/526,979	07/30/2019	N/A	N/A	HOMOGENOUS ANTIBODY DRUG CONJUGATES VIA ENZYMATIC METHODS
EP	15806587.0	06/11/2015 (Int'l Date)	N/A	N/A	HOMOGENOUS ANTIBODY DRUG CONJUGATES VIA ENZYMATIC METHODS
AU	2015274506	06/11/2015 (Int'l Date)	N/A	N/A	HOMOGENOUS ANTIBODY DRUG CONJUGATES VIA ENZYMATIC METHODS
CA	2,951,887	06/11/2015 (Int'l Date)	N/A	N/A	HOMOGENOUS ANTIBODY DRUG CONJUGATES VIA ENZYMATIC METHODS
PCT	PCT/US2020/057761	10/28/2020	N/A	N/A	COMPOSITIONS AND METHODS FOR TREATING CANCERS USING ANTI-HER2 ANTIBODY DRUG CONJUGATE

ENTITY TO ENTITY ASSIGNMENT

This Assignment is by:

Assignor: CSPC Dopphen Corporation
Address: 4070 Truxel Road
Sacramento, California 95834
A juristic entity duly organized under and pursuant to the laws of: Delaware

(referred to in this Assignment as "Assignor"), which is the sole and exclusive owner, by assignment, of the patents and applications identified in Exhibit A.

This Assignment is to:

Assignee: CSPC Megalith Biopharmaceutical Co., Ltd.
Address: 226 Huanghe Avenue
Shijiazhuang, Hebei, China
A juristic entity duly organized under and pursuant to the laws of: China

(referred to in this Assignment as "Assignee"), which desires to acquire the entire right, title and interest in, to and under said patent application and the inventions covered thereby.

For good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and to the extent that the Assignor has not done so already via a prior agreement with the Assignee or a predecessor in interest of the Assignee, or if the Assignor has already done so via a prior agreement with the Assignee or a predecessor in interest of the Assignee then in confirmation of any obligation to do so in said prior agreement

1. Assignor hereby sells, assigns, transfers and sets over, to Assignee, its successors, legal representatives and assigns, Assignor's entire right, title and interest in and to the above-mentioned inventions, application for letters patent, and any and all non-provisionals, divisions, continuations, and continuations-in part claiming priority thereto or the benefit thereof, substitutions of said applications, and any and all letters patent or patents in the United States of America and all foreign countries or jurisdictions which may be granted therefor and thereon, including, without limitation, any modifications to such letters patent or patents such as through reissue, re-examination or other post-grant proceeding, and any and all extensions of said letters patent or patents, and all rights under the International Convention for the Protection of Industrial Property, the same to be held and enjoyed by Assignee (including any right to institute actions and to recover damages for past, present and future infringement, and any and all rights to claim priority to said application and any and all applications claiming priority thereto or based on said inventions), for its own use and the use of its successors, legal representatives and assigns, to the full end of the term or terms for which letters patent or patents may be granted, as fully and entirely as the same would have been held and enjoyed by Assignor, had this sale and assignment not been made.

2. Assignor hereby authorizes and requests the Commissioner for Patents in the United States to issue the above mentioned letters patents of the United States and any reissue, reexamination, review, or extension thereof to and in the name of Assignee as the assignee of said inventions and the letters patent to be issued thereon for the sole use of Assignee, its successors, legal representatives and assigns.

3. Assignor hereby grants Assignee's attorneys, all of Morrison & Foerster LLP (or as needed attorneys of the applicable country appointed and authorized by Morrison & Foerster LLP), the power to insert on this assignment any further identification which may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark office or any foreign patent issuing authority for recordation of this document, including the power to insert on this assignment the application number and filing date of said application when known.

4. This assignment may be executed in one or more counterparts, with the same effect as if each signature were on the same document. Each counterpart so executed shall be deemed to be an original, and all such counterparts shall be construed together and shall constitute one agreement.

In witness whereof, executed by the undersigned on the date(s) opposite the undersigned name(s).

ASSIGNOR:

Date:

Signature:

Name:

Title:

Company: CSPC Dophen Corporation

ASSIGNEE:

Date: 2012.02.21

Signature: Bing Yao

Name: Bing Yao

Title: President

Company: CSPC Megalith Biopharmaceutical Co., Ltd.

Exhibit A

Country	Application No.	Filing Date	Patent No.	Issue Date	Title
US	15/317,907	06/11/2015 (Int'l Date)	10,357,472	07/23/2019	HOMOGENOUS ANTIBODY DRUG CONJUGATES VIA ENZYMATIC METHODS
US	15/986,665	05/22/2018	10,639,291	05/05/2020	HOMOGENOUS ANTIBODY DRUG CONJUGATES VIA ENZYMATIC METHODS
US	15/986,668	05/22/2018	10,471,037	11/12/2019	HOMOGENOUS ANTIBODY DRUG CONJUGATES VIA ENZYMATIC METHODS
US	16/526,979	07/30/2019	N/A	N/A	HOMOGENOUS ANTIBODY DRUG CONJUGATES VIA ENZYMATIC METHODS
EP	15806587.0	06/11/2015 (Int'l Date)	N/A	N/A	HOMOGENOUS ANTIBODY DRUG CONJUGATES VIA ENZYMATIC METHODS
AU	2015274506	06/11/2015 (Int'l Date)	N/A	N/A	HOMOGENOUS ANTIBODY DRUG CONJUGATES VIA ENZYMATIC METHODS
CA	2,951,887	06/11/2015 (Int'l Date)	N/A	N/A	HOMOGENOUS ANTIBODY DRUG CONJUGATES VIA ENZYMATIC METHODS
PCT	PCT/US2020/057761	10/28/2020	N/A	N/A	COMPOSITIONS AND METHODS FOR TREATING CANCERS USING ANTI-HER2 ANTIBODY DRUG CONJUGATE

sf-4685642